Advertisement
Singapore markets close in 6 hours 4 minutes
  • Straits Times Index

    3,288.68
    +0.93 (+0.03%)
     
  • Nikkei

    37,780.35
    +151.87 (+0.40%)
     
  • Hang Seng

    17,564.00
    +279.46 (+1.62%)
     
  • FTSE 100

    8,078.86
    +38.48 (+0.48%)
     
  • Bitcoin USD

    64,500.77
    +261.23 (+0.41%)
     
  • CMC Crypto 200

    1,390.99
    +8.41 (+0.61%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • Dow

    38,085.80
    -375.12 (-0.98%)
     
  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     
  • Gold

    2,344.40
    +1.90 (+0.08%)
     
  • Crude Oil

    83.77
    +0.20 (+0.24%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • FTSE Bursa Malaysia

    1,572.61
    +3.36 (+0.21%)
     
  • Jakarta Composite Index

    7,107.43
    -47.86 (-0.67%)
     
  • PSE Index

    6,557.16
    -17.72 (-0.27%)
     

Puma Biotechnology: Recent Developments and Recommendations

Puma Biotechnology: Recent Developments and Recommendations

In June, the Committee for Medicinal Products for Human Use recommended a favorable opinion on the approval of Puma Biotechnology’s (PBYI) Nerlynx for its commercialization in the European Union for the prolonged adjuvant therapy of adults with early-stage HER2+ (hormone-receptor-positive) breast cancer whose prior adjuvant trastuzumab-based therapy is less than one year from completion.